Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Accumulated Expenses (2017 - 2023)

Arcus Biosciences (RCUS) has 7 years of Accumulated Expenses data on record, last reported at $12.0 million in Q1 2023.

  • For Q1 2023, Accumulated Expenses rose 2.87% year-over-year to $12.0 million; the TTM value through Mar 2023 reached $12.0 million, up 2.87%, while the annual FY2022 figure was $25.0 million, 47.06% up from the prior year.
  • Accumulated Expenses reached $12.0 million in Q1 2023 per RCUS's latest filing, down from $25.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $25.0 million in Q4 2022 and bottomed at $2.6 million in Q1 2020.
  • Average Accumulated Expenses over 5 years is $11.1 million, with a median of $9.7 million recorded in 2019.
  • Peak YoY movement for Accumulated Expenses: crashed 35.34% in 2020, then surged 177.79% in 2021.
  • A 5-year view of Accumulated Expenses shows it stood at $5.0 million in 2019, then surged by 92.79% to $9.5 million in 2020, then skyrocketed by 78.14% to $17.0 million in 2021, then skyrocketed by 47.06% to $25.0 million in 2022, then plummeted by 52.0% to $12.0 million in 2023.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $12.0 million in Q1 2023, $25.0 million in Q4 2022, and $20.5 million in Q3 2022.